フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
City of Hope, a leader in cancer research and treatment, was awarded $5.3 million from California Institute for Regenerative Medicine (CIRM) to...
City of Hope was awarded $5.3 million from CIRM to develop a treatment for metastatic ovarian cancer using Calidi’s licensed lead asset...
– Preclinical models have demonstrated the ability to resist oncolytic virus inactivation by human serum and target diverse tumor types – Novel...
Antonio Chiocca, M.D., Ph.D., Chair, Department of Neurosurgery at Brigham and Women’s Hospital, Co-Director, Institute for the Neurosciences...
Company to also share progress with cell-based virotherapy platforms for advanced solid tumors Calidi Biotherapeutics, Inc. (NYSE American: CLDI...
Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
Announced first patient dosed by collaborator City of Hope in a Phase 1 clinical trial evaluating CLD-101 in recurrent high-grade glioma patients...
Poster also details clinical readiness for CLDI-201 and plans to initiate Phase 1 study in 2024 Calidi Biotherapeutics, Inc. (NYSE American: CLDI...
Antonio F. Santidrian, PharmD, Ph.D., promoted to Chief Scientific Officer and Amish Patel, Ph.D., promoted to Senior Vice President of Technical...
Calidi Biotherapeutics, Inc. (NYSEAM: CLDI) (or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023 Gross...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
サインアップして広告なしのエクスペリエンスを体験してください
今すぐ試してください
広告を残す